Data

APML4 A phase II trial in patients with previously untreated acute promyelocytic leukaemia to evaluate the effects of: (i) adding arsenic trioxide to all-trans retinoic acid and idarubicin for remission induction, and (ii) adding arsenic trioxide to all-trans retinoic acid as consolidation

Health Data Australia Contributor Records
Iland, Harry ; Australasian Leukaemia And Lymphoma Group (ALLG) ; Australasian Leukaemia And Lymphoma Group (ALLG)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/YEN7-MB13&rft.title=APML4 A phase II trial in patients with previously untreated acute promyelocytic leukaemia to evaluate the effects of: (i) adding arsenic trioxide to all-trans retinoic acid and idarubicin for remission induction, and (ii) adding arsenic trioxide to all-trans retinoic acid as consolidation&rft.identifier=http://doi.org/10.58109/YEN7-MB13&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=Dataset includes: Data on 200 patients with acute non-lymphocytic leukaemia . High dose Ara-C daunorubicin and VP16-213 (HIDAC-37) versus conventional dose and complete remission in adults. Remission duration/survival. Toxicity of two treatment arms. Prognostic variables. Cytogenetics.&rft.creator=Iland, Harry &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12605000070639&rft_subject=Cancer therapy (excl. chemotherapy and radiation therapy)&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

Dataset includes: Data on 200 patients with acute non-lymphocytic leukaemia . High dose Ara-C daunorubicin and VP16-213 (HIDAC-37) versus conventional dose and complete remission in adults. Remission duration/survival. Toxicity of two treatment arms. Prognostic variables. Cytogenetics.

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Subjects
Cancer therapy (excl. chemotherapy and radiation therapy) |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

doi : https://doi.org/10.1182/blood-2012-02-410746

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

doi : http://doi.org/10.1016/S2352-3026(15)00115-5

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

doi : http://doi.org/10.1182/blood-2016-10-747170

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Identifiers